DREADD: a chemogenetic GPCR signaling platform
H Zhu, BL Roth - International Journal of …, 2015 - academic.oup.com
H Zhu, BL Roth
International Journal of Neuropsychopharmacology, 2015•academic.oup.comRecently, we created a family of engineered G protein-coupled receptors (GPCRs) called
DREADD (designer receptors exclusively activated by designer drugs) which can precisely
control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has
been successfully applied in a variety of in vivo studies to control GPCR signaling, and here
we describe recent advances of DREADD technology and discuss its potential application in
drug discovery, gene therapy, and tissue engineering.
DREADD (designer receptors exclusively activated by designer drugs) which can precisely
control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has
been successfully applied in a variety of in vivo studies to control GPCR signaling, and here
we describe recent advances of DREADD technology and discuss its potential application in
drug discovery, gene therapy, and tissue engineering.
Abstract
Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering.
Oxford University Press